Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598871 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds
A Phase 2 study, sponsored by ReGenTree.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT00598871 is a Phase 2 study that was terminated before completion, run by ReGenTree. The registered enrollment target is 12 participants.
The verdict
NCT00598871, a Phase 2 study, was terminated before completion, sponsored by ReGenTree.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
As a consequence of damage to multiple organ systems throughout the course of their disease, diabetic patients suffer a number of chronic complications giving rise to increased morbidity, mortality, and health care costs specific to this population. Within the ophthalmic domain, diabetic retinopathy (DR) frequently induces serious visual impairment. Although DR can be addressed surgically, surgery remains a less than ideal intervention within this population with a well-characterized compromised ability to heal. The introduction of a therapeutic agent that could accelerate wound closure and decrease healing time, thereby reducing the risk and incidence of infection and corneal scarring in these susceptible patients, would represent a significant clinical and pharmacoeconomic advance in the treatment of this condition.
Interventions
- OTHER Placebo
- DRUG Thymosin Beta 4 (Tβ4)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598871
The ClinicalTrials.gov registry entry for NCT00598871 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ReGenTree, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00598871 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00598871 about?
NCT00598871 is a clinical study titled "A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds". As a consequence of damage to multiple organ systems throughout the course of their disease, diabetic patients suffer a number of chronic complications giving rise to increased morbidity, mortality, and health care costs specific to this population. Within the ophthalmic domain, diabetic retinopathy...
What is the current status of trial NCT00598871?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2007-12. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00598871?
The interventions under investigation include: Placebo (OTHER), Thymosin Beta 4 (Tβ4) (DRUG).
Who is sponsoring clinical trial NCT00598871?
This trial is sponsored by ReGenTree, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.